Shares of health-care companies rose as a rebound in risk tolerance buoyed biotech stocks. Gilead Sciences doubled down on an experimental cellular therapy it entered with the $11 billion purchase of Kite Pharma, agreeing to buy Cell Design Labs for $175 million. CVS Health expects the antitrust review of its proposed acquisition of health insurer Aetna to be handled by the Justice Department, a route that some analysts predict will be tougher than the relatively smooth path foreseen in a Federal Trade Commission review of the deal.
-Rob Curran, email@example.com
Continue Reading Below
(END) Dow Jones Newswires
December 08, 2017 16:17 ET (21:17 GMT)